Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

被引：0
|
作者：
van Meerten, Tom [1 ]
Kersten, M. J. [2 ]
Lacoboni, Gloria [3 ]
Hess, Georg [4 ]
Mutsaers, Pim [5 ]
Garcia-Sancho, Alejandro Martin [6 ]
Goy, Andre [7 ]
Gine, Eva [8 ]
Hill, Brian T. [9 ]
Weng, Wen-Kai [10 ]
Dreyling, Martin [11 ]
Reagan, Patrick M. [12 ]
Patel, Krish [13 ]
Galal, Ahmed [14 ]
Herbaux, Charles [15 ]
Sanderson, Robin [16 ]
Zheng, Dan [17 ]
Kanska, Justyna [17 ]
Zhang, Wangshu [17 ]
Khalid, Rita Damico [17 ]
Kloos, Loana [17 ]
Wang, Michael [18 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands
[2] Locat Univ Amsterdam, Canc Ctr Amsterdam, Amsterdam UMC, Amsterdam, Netherlands
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Johannes Gutenberg Univ Mainz, Mainz, Germany
[5] Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands
[6] Salamanca Univ Hosp, Hematol Dept, IBSAL, CIBERONC, Salamanca, Spain
[7] John Theurer Canc Ctr, Hackensack, NJ USA
[8] Hosp Clin Barcelona, IDIBAPS, CIBERONC, Barcelona, Spain
[9] Cleveland Clin Fdn, Cleveland, OH USA
[10] Stanford Univ, Div Blood & Marrow Transplantat & Cellular Therapy, Sch Med, Palo Alto, CA USA
[11] Ludwig Maximilian Univ Hosp, Dept Med 3, Munich, Germany
[12] Univ Rochester, Med Ctr, Rochester, NY USA
[13] Swedish Canc Inst, Seattle, WA USA
[14] Carol G Simon Canc Ctr, Morristown, NJ USA
[15] CHU Montpellier, Hematol Clin, Montpellier, France
[16] Kings Coll Hosp London, London, England
[17] Kite Gilead Co, Santa Monica, CA USA
[18] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-198021
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：748 / 750
页数：3
相关论文
共 36 条
  • [1] Outcomes of Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 and ZUMA-18, an Expanded Access Study
    Goy, Andre
    Jacobson, Caron A.
    Flinn, Ian W.
    Hill, Brian T.
    Weng, Wen-Kai
    Mountjoy, Luke
    Olalekan, Oluwole
    Zheng, Dan
    Nunes, Ana
    Zhang, Wangshu
    Shen, Rhine R.
    Kloos, Ioana
    Wang, Michael L.
    BLOOD, 2023, 142
  • [2] Assessment of durable responses after brexucabtagene autoleucel (brexu-cel) in relapsed/refractory mantle cell lymphoma (R/R MCL)
    Pindoria, Lohit
    Munoz, Javier
    Reagan, Patrick
    Goy, Andre
    Miklos, David
    Zheng, Dan
    Fang, Xiang
    Shen, Rhine
    Siddiqi, Rubina
    Kloos, Ioana
    Kersten, Marie Jose
    Wang, Michael
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 113 - 114
  • [3] A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)
    Hess, Georg
    Dreyling, Martin
    Oberic, Lucie
    Gine, Eva
    Zinzani, Pier Luigi
    Linton, Kim M.
    Vilmar, Adam
    Jerkeman, Mats
    Chen, Jenny M. H.
    Ohler, Anke
    Stilgenbauer, Stephan
    Thieblemont, Catherine
    Lambert, Jonathan
    Zilioli, Vittorio Ruggero
    Sancho, Juan-Manuel
    Jimenez-Ubieto, Ana
    Fischer, Luca
    Eyre, Toby A.
    Keeping, Sam
    Park, Julie E.
    Wu, James J.
    Siddiqi, Rubina
    Reitan, John
    Castaigne, Gab
    Salles, Gilles
    BLOOD, 2022, 140 : 10296 - 10299
  • [4] Brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma (R/R MCL) in ZUMA-2: Durable responder analysis
    Munoz, Javier
    Reagan, Patrick M.
    Goy, Andre
    Miklos, David B.
    Zheng, Dan
    Fang, Xiang
    Shen, Rhine R.
    Siddiqi, Rubina
    Kloos, Ioana
    Kersten, Marie Jose
    Wang, Michael
    ANNALS OF ONCOLOGY, 2023, 34 : S1380 - S1380
  • [5] Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel ( Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2
    Oluwole, Olalekan O.
    Reagan, Patrick M.
    Miklos, David B.
    Locke, Frederick L.
    Goy, Andre
    Jacobson, Caron A.
    Munoz, Javier L.
    Forcade, Edouard
    Topp, Max S.
    Zheng, Dan
    Nunes, Ana
    Zhang, Wangshu
    Shen, Rhine R.
    Kloos, Ioana
    Kersten, Marie Jose
    Wang, Michael L.
    BLOOD, 2023, 142
  • [6] Matching-Adjusted Indirect Comparison (MAIC) of Brexucabtagene Autoleucel (Brexu-cel) and Pirtobrutinib in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)
    Chen, Jenny M. H.
    Zhang, Ina
    Wu, James J.
    Wade, Sally W.
    Nunes, Ana
    Peng, Weimin
    Snider, Julia T.
    Maciel, Dylan
    Chan, Keith
    Keeping, Sam
    Shah, Bijal D.
    BLOOD, 2023, 142
  • [7] Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment.
    Kambhampati, Swetha
    Ahmed, Nausheen
    Hamadani, Mehdi
    Grover, Natalie Sophia
    Shadman, Mazyar
    Locke, Frederick L.
    Gerson, James M.
    Frank, Matthew Joshua
    Budde, Lihua Elizabeth
    Wang, Michael
    Hu, Zhen-Huan
    Nunes, Ana
    Dalton, David
    Kloos, Ioana
    Lee, Daniel
    Xu, Hairong
    Pasquini, Marcelo C.
    Herrera, Alex Francisco
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Real-World Outcomes of Brexucabtagene Autoleucel ( Brexu-cel) for Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A CIBMTR Subgroup Analysis of High-Risk Characteristics
    Kambhampati, Swetha
    Ahmed, Nausheen
    Hamadani, Mehdi
    Kim, Soyoung
    Hemmer, Michael T.
    Grover, Natalie S.
    Shadman, Mazyar
    Beitinjaneh, Amer
    Budde, L. Elizabeth
    Gerson, James
    Jacobson, Caron A.
    Locke, Frederick L.
    Nasta, Dwivedy S.
    Wang, Michael L.
    Weng, Wen-Kai
    Yan, Jiali
    Nunes, Ana
    Dalton, David
    Wu, James J.
    Abdeldaim, Amina
    Hu, Zhen-Huan
    Pasquini, Marcelo
    Herrera, Alex F.
    BLOOD, 2023, 142
  • [9] Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/ Refractory Mantle Cell Lymphoma (R/R MCL)
    Munoz, Javier
    Reagan, Patrick M.
    Goy, Andre H.
    Miklos, David B.
    Zheng, Dan
    Fang, Xiang
    Shen, Rhine R.
    Siddiqi, Rubina
    Kloos, Ioana
    Kersten, Marie Jose
    Wang, Michael
    BLOOD, 2022, 140 : 9320 - 9322
  • [10] Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial
    Wang, Michael
    Rossi, John M.
    Munoz, Javier
    Goy, Andre H.
    Locke, Frederick L.
    Reagan, Patrick M.
    Jacobson, Caron A.
    Hill, Brian T.
    Holmes, Houston
    Jaglowski, Samantha
    Peng, Weimin
    Zheng, Lianqing
    Fang, Xiang
    Xue, Allen
    Kloos, Ioana
    Bot, Adrian
    BLOOD, 2020, 136
1234